- Hypersensitivity to one or both ingredients of the 
   product.

  Due to the limited systemic availability after vaginal 
  application, clinically relevant interactions occur very 
  rarely.
- In patients on oral anticoagulants, such as warfarin, caution 
  should be considered and the anticoagulant effect should be 
  monitored , because anticoagulants activity can be 
  potentiated by product  administrated intravaginally . 
- Contact should be avoided between latex products (such as 
  contraceptive diaphragms and condoms) and Gyno-M®  
  vaginal ovules, since intravaginal preparations of 
  Gyno-M® may damage them. 
- The effects and side effects of some other drugs (e.g., oral 
  hypoglycemic and phenytoin), when co-administered with 
  Gyno-M®, can be increased and caution should be 
  exercised 

- Use during pregnancy : As systemic intravaginal 
  absorption of miconazole nitrate is limited, no adverse 
  effects have been reported when using of Gyno-M®, 
  however it  is preffered to not be used during the first 
  trimester of pregnancy, unless  when considered essential 
  to the welfare of the patient.
- Use during lactation :It is unknown whether intravaginal 
  miconazole is excreted in breast milk . 
  However, problems in humans have not been documented, 
  caution should be considered . 

- Gyno-M® vaginal ovules are usually well tolerated. 
  some adverse reactions have rarely been reported 
  including local irritation or sensitivity include mild 
  burning sensation, erythema, and vaginal itching, 
  vaginal discharge, abdominal cramps, headache, 
  especially at the beginning of treatment. 

- If local irritation and hypersensitivity reactions occur, 
  treatment should be discontinued .
- General hygienic measures should be observed to control 
  sources of infection or reinfection.
- Appropriate therapy is indicated when the husband partner 
  is also infected.

- Gyno-M® ovules : pack contains  3 ovules .
 

- Store below  25 °C.